Cytokinetics, Incorporated (CYTK)
Nasdaq: CYTK · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2003
Who owns Cytokinetics, Incorporated
As filed with the SECHolders of 5% or more
3
T. Rowe Price Investment Management, Inc. holds 14.5% of COMMON STOCK, as its SCHEDULE 13G/A filed Feb 17, 2026 says.
Directors and officers
14
report now, of 32 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed Feb 17, 2026 · COMMON STOCK · 16% in Nov 14, 2025
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Nov 10, 2025 · COMMON STOCK · reported falling below 5%
Fmr LLC
SCHEDULE 13G/A · filed Jul 8, 2026 · COMMON STOCK · reported falling below 5%, from 9% in May 6, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 10.1% in Jan 8, 2025
What CYTK reports owning in othersstakes of 5% or more, and other ties
Cytokinetics, Incorporated reports no stake in another company in the record.
Insider tradesForm 4
86sales
0purchases
76sales on a scheduled plan
10people selling
$52.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 42 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO | 20 | $17.6M | 17 | 0 | $0 |
| Callos Andrew | EVP, Chief Commercial Officer | 25 | $16.0M | 22 | 0 | $0 |
| Lee Sung | EVP, Chief Financial Officer | 5 | $5.7M | 4 | 0 | $0 |
| Malik Fady Ibraham | EVP Research & Development | 21 | $4.9M | 18 | 0 | $0 |
| Henderson John T | director | 2 | $2.1M | 2 | 0 | $0 |
| Kaye Edward M. Md | director | 2 | $2.1M | 2 | 0 | $0 |
| Parshall B Lynne | director | 6 | $1.6M | 6 | 0 | $0 |
| Wierenga Wendell | director | 2 | $1.6M | 2 | 0 | $0 |
| Harrington Robert Arthur | director | 1 | $100,000 | 1 | 0 | $0 |
| Landry Robert E | director | 2 | $100,000 | 2 | 0 | $0 |